Zoetis Elects New Board Member at Annual Meeting

Zoetis ( (ZTS) ) has issued an announcement.

On May 21, 2025, Zoetis Inc. held its Annual Meeting of Shareholders, where Dr. Mark Stetter was elected to the Board of Directors, succeeding Mr. Robert Scully who retired in accordance with the company’s director retirement policy. Dr. Stetter, with extensive experience in veterinary medicine and animal health, is expected to contribute significantly to Zoetis’ mission of advancing animal care. The meeting also saw the election of twelve directors, approval of the executive compensation program, and ratification of KPMG LLP as the independent registered public accounting firm, though a shareholder proposal for special meeting improvements was not approved.

The most recent analyst rating on (ZTS) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.

Spark’s Take on ZTS Stock

According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.

Zoetis scores highly due to its strong financial performance, robust earnings call outlook, and positive technical indicators. While the high P/E ratio suggests overvaluation concerns, the company’s strategic resilience and growth in key segments support a bullish outlook. Debt levels require careful management to mitigate risk.

To see Spark’s full report on ZTS stock, click here.

More about Zoetis

Zoetis is the world’s leading animal health company, focusing on advancing care for animals through innovative medicines, vaccines, diagnostics, and technologies. With a presence in over 100 countries, Zoetis serves veterinarians, pet owners, and livestock producers. In 2024, the company generated $9.3 billion in revenue and employs approximately 13,800 people.

Average Trading Volume: 2,934,961

Technical Sentiment Signal: Sell

Current Market Cap: $72.86B

Learn more about ZTS stock on TipRanks’ Stock Analysis page.